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Introduction 
 
The mitochondria are the power plants of the cell; when 
they are unable to meet the brain’s substantial energy 
demands, neurodegeneration occurs.  Leigh syndrome 
(LS) and Neuropathy, Ataxia, and Retinitis Pigmentosa 
(NARP) are two such neurodegenerative diseases, and 
are caused by dysfunctional ATP synthase.  This 
enzyme is composed of fifteen subunits that work 
together to couple the flow of protons into the 
mitochondrial matrix to a rotating complex that 
catalyzes the ADP + Pi  ATP reaction (Baracca et al., 
2000; Elston et al., 1998).  Specifically, the ATP6 gene 
that is encoded in the mitochondrial genome forms the 
proton channel subunit of ATP synthase (Baracca et al., 
2000; Elston et al., 1998).  In LS and NARP patients, 
the ATP6 gene contains either a T8993G (Holt et al., 
1990) or much less common T8993C (deVries et al., 
1993) nucleotide mutation.  Consequently, proton 
conductance is reduced and ATP synthesis as well as 
holoenzyme assembly is decreased (Trounce et al., 
1994; Garcia et al., 2000; Baracca et al., 2000).  
Because ATP6 is a mitochondrial gene, LS and NARP 
syndromes are maternally inherited and result when the 
cellular heteroplasmy (mutant dosage) is 90-95% and 
70-90%, respectively (Tautch et al., 1992). 
 My research interests focus on the 
development of a gene therapy solution for LS and 
NARP syndromes that increases ATP synthesis.  In 
addition to ATP synthase dysfunction, the T8993G 
mutation results in increased levels of reactive oxygen 
species (ROS), which induce an increase in the 
expression of the free-radical scavenging superoxide 
dismutases (SOD) and trigger apoptosis (Geromel et 
al., 2001).  Furthermore, oxidative stress damages 
mitochondrial lipids and impairs function of the election 
transport chain, consequently decreasing ATP 
synthesis (Mattiazzi et al., 2004).  ATP synthesis 
increases after antioxidant treatment of 100% 
(homoplasmic) T8993G cybrids synthesized from 
enucleated plate cells and osteosarcoma cells 
(Mattiazzi et al, 2004). 
 The most promising possibility for increasing 
ATP synthesis and ATP synthase function in LS and 
NARP cells arises from the success of allotropic 
expression of wild-type (WT) ATP6 within homoplasmic 
T8993G Human Embryonic Kidney (HEK) cells 
(Manfredi et al., 2002).  This is achieved through the 
use of a recombinant Adeno Associated Virus (AAV) to 
deliver WT-ATP6 into the nuclear genome (i.e. Allotopic 
Expression; Manfredi et al., 2002).  ATP synthesis is 
significantly increased in HEK cells allotopically 
expressing WT-ATP6 compared to non-treated 
mutants; however, it remains to be discovered whether 
the increase in WT-ATP6 expression will increase ATP 
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synthesis above the disease-causing threshold 
(Manfredie et al., 2002).   
 Because allotopic expression of WT-ATP6 
and treatment of T8993G homoplasmic cells with 
antioxidants both increase ATP synthesis, I propose 
combining these two approaches into one that employs 
the AAV vector developed by Manfredi et al. (2002), 
modified to contain the nuclear encoded mitochondrial 
manganese superoxide dismutase gene (MnSOD) and 
WT-ATP6 (Geromel et al., 2001). MnSOD is a free-
radical scavenging enzyme that has increased 
expression in T8993G cells (Mattiazzi et al., 2004; 
Geromel et al., 2001).  I believe overexpression of 
MnSOD in combination with allotopically expressed 
WT-ATP6 will increase ATP synthesis compared to 
primary T8993G neurons that allotopically express WT-
ATP6 only (Geromel et al., 2001; Mattiazzi et al., 2004; 
Manfredi et al., 2002).  Thus, the combined ATP 
synthesis increasing effects of replenishing WT-ATP6 
and reducing oxidative stress may increase respiratory 
efficiency enough to prevent neuronal atrophy.  
 
Specific Aims 
 
Determine if ATP synthesis is increased in LS and 
NARP patient brainstem neurons by treatment with 
either the WT-ATP6-AAV vector developed by Manfredi 
et al. (2002) or the antioxidant DHLPA (Mattiazzi et al., 
2004). 
Increase ATP synthesis in neurons from Aim 
1 by reducing the concentration of ROS and 
dysfunctional ATP synthase via the Manfredi et al. WT-
ATP6 AAV vector modified to include MnSOD (2002). 
 
Experimental Proposal 
 
In order to accomplish Aim 1, brainstem neurons will be 
harvested upon autopsy from LS and NARP patients as 
well as decreased neurologically intact individuals.  I 
hypothesize that allotopic expression of WT-ATP6 
using the AAV vector developed by Manfredi et al. 
(2002) will significantly increase ATP synthesis in LS 
and NARP patient neurons based on the Manfredi et al. 
findings in T8993G homoplasmic HEK cells (2002).  
Furthermore, I hypothesize that treatment of LS and 
NARP patient neurons with the antioxidant dihydrolipoic 
acid (DHLPA) will increase ATP synthesis based on the 
Mattiazzi et al. results in T8993G homoplasmic cybrids 
(2004).  This first experiment is essentially a repeat of 
the Mattiazzi et al. (2004) and Manfredi et al. (2002) 
studies because neither have been performed on 
primary neuron cultures and further support of their 
conclusions is needed to pursue either as a future 
treatment strategy. 
 The Manfredi et al. AAV vector containing 
WT-ATP6 tagged with a mitochondrial localization 
signal (MLS) will be incubated with mutant neuronal 
cultures (2002).  Experimental controls will consist of 
mutant and WT neurons treated with an empty AAV 
vector, and WT neurons with WT-ATP6-AAV as well.  
These controls allow us to determine if any changes in 
ATP synthesis in the mutants are the result of WT-
ATP6 expression only.  ATP synthesis will be measured 
using the method described by Manfredi et al. (2001).  
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If ATP synthesis in mutants increases, then we 
conclude that it resulted from competition between WT 
and mutant ATP6 during ATP synthase assembly, and 
that the concentration of WT-ATP synthase had 
increased in the mitochondria.  However, if ATP 
synthesis does not increase, it is possible that the 
increase in ATP synthesis observed by Manfredi et al. 
in HEK cells was cell-type specific (2002).  An identical 
experimental setup will be performed for cells treated 
with the antioxidant DHLPA as described by Mattiazzi 
et al. (2004), with controls consisting of 1) treatment or 
2) no treatment of WT and mutant cells.  If ROS 
particles are causing electron transport chain 
dysfunction, then we expect to see an increase in ATP 
synthesis for both LS and NARP cells treated with 
DHLPA.  If we do not observe a significant increase in 
ATP synthesis, we cannot conclude that ROS are not 
involved because the types of ROS generated in 
neurons and consumed by DHLPA may differ from 
those in the Mattiazzi et al. cybrids (2004). 
 Increased MnSOD activity is 
associated with cells homoplasmic for the T8993G-
ATP6 mutation (Geromel et al., 2001; Mattiazzi et al., 
2004).  This enzyme is critical to reducing the presence 
of ROS within the mitochondria and protecting the cell 
from oxidative stress.  The MnSOD gene is encoded in 
the nuclear genome and contains a MLS; thus, there is 
no need for genetic modification before it is cloned into 
the AAV genome containing WT-ATP6 (Manfredi et al., 
2002).  I hypothesize that overexpression of MnSOD in 
combination with allotopic WT-ATP6 expression will 
significantly increase ATP synthesis compared to only 
allotopic WT-ATP6 expression in mutant neurons.  The 
experimental setup will consist of WT and mutant 
neurons receiving 1) empty AAV vector or 2) the WT-
ATP6+MnSOD-AAV construct.  LS and NARP cells will 
be infected with the virus containing both WT-ATP6 and 
MnSOD in its genome, and ATP synthesis measured as 
described by Manfredi et al. (2001).  If T8993G mutant 
cells overexpressing MnSOD and allotopically 
expressing WT-ATP6 have increased ATP synthesis 
compared to those treated with the WT-ATP6-AAV 
construct from Aim 1, we can conclude that reduction of 
ROS within the mitochondria by MnSOD 
overexpression increases ATP synthesis.  In contrast, if 
we observe identical ATP synthesis between both AAV 
constructs, then MnSOD overexpression has no effect 
on ATP synthesis. 
 
Conclusion 
 
The proposed experiments will contribute significantly 
to the development of a gene therapy approach to 
increasing ATP synthesis in LS and NARP patients.  
Specifically, combining two previously established 
methods for increasing ATP synthesis in homoplasmic 
T8993G-ATP6 cells into one viral expression system 
may provide the critical increase in ATP synthesis 
necessary to prevent LS and NARP manifestation 
(Manfredi et al., 2002; Geromel et al., 2001; Mattiazzi et 
al., 2004). 
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